Department of Perioperative Medicine and Intensive Care, Karolinska University Hospital, Solna, Stockholm, Sweden.
Section of Anaesthesiology and Intensive Care Medicine, Department of Physiology and Pharmacology, Karolinska Institute, Stockholm, Sweden.
Crit Care Explor. 2024 Jul 8;6(7):e1124. doi: 10.1097/CCE.0000000000001124. eCollection 2024 Jul.
Exposure to critical illness and intensive care may lead to long-term psychologic and physical impairments. To what extent ICU survivors become prolonged users of benzodiazepines after exposure to critical care is not fully explored. This study aimed to describe the extent of onset of prolonged high-potency benzodiazepine use among ICU survivors not using these drugs before admission, identify factors associated with this use, and analyze whether such usage is associated with increased mortality.
Retrospective cohort study.
Sweden, including all registered ICU admissions between 2010 and 2017.
ICU patients surviving for at least 3 months, not using high-potency benzodiazepine before admission, were eligible for inclusion.
Admission to intensive care.
A total of 237,904 patients were screened and 137,647 were included. Of these 5338 (3.9%) became prolonged users of high-potency benzodiazepines after ICU discharge. A peak in high-potency benzodiazepine prescriptions was observed during the first 3 months, followed by sustained usage throughout the follow-up period of 18 months. Prolonged usage was associated with older age, female sex, and a history of both somatic and psychiatric comorbidities, including substance abuse. Additionally, a longer ICU stay, a high estimated mortality rate, and prior consumption of low-potency benzodiazepines were associated with prolonged use. The risk of death between 6 and 18 months post-ICU admission was significantly higher among high-potency benzodiazepine users, with an adjusted hazard ratio of 1.8 (95% CI, 1.7-2.0; < 0.001). No differences were noted in causes of death between users and nonusers.
Despite the lack of evidence supporting long-term treatment, prolonged usage of high-potency benzodiazepines 18 months following ICU care was notable and associated with an increased risk of death. Considering the substantial number of ICU admissions, prevention of benzodiazepine misuse may improve long-term outcomes following critical care.
暴露于危重病和重症监护可能导致长期的心理和身体损伤。在重症监护中接触到的 ICU 幸存者在多大程度上成为长期使用苯二氮䓬类药物的患者,这一点尚未得到充分探索。本研究旨在描述在进入重症监护病房前未使用这些药物的 ICU 幸存者开始长期使用高剂量苯二氮䓬类药物的程度,确定与这种使用相关的因素,并分析这种使用是否与死亡率增加有关。
回顾性队列研究。
瑞典,包括 2010 年至 2017 年间所有登记的 ICU 入院患者。
至少存活 3 个月、入院前未使用高剂量苯二氮䓬类药物的 ICU 患者有资格入选。
入住重症监护病房。
共筛选了 237904 名患者,其中 137647 名患者入选。其中 5338 名(3.9%)患者在 ICU 出院后成为高剂量苯二氮䓬类药物的长期使用者。在最初的 3 个月内观察到高剂量苯二氮䓬类药物处方的峰值,随后在 18 个月的随访期间持续使用。长期使用与年龄较大、女性、躯体和精神合并症(包括药物滥用)的既往史相关。此外,ICU 住院时间较长、估计死亡率较高以及之前使用低剂量苯二氮䓬类药物也与长期使用相关。ICU 入院后 6 至 18 个月之间,高剂量苯二氮䓬类药物使用者的死亡风险显著更高,调整后的风险比为 1.8(95%CI,1.7-2.0;<0.001)。在使用者和非使用者之间,死亡原因无差异。
尽管缺乏长期治疗的证据,但在重症监护后 18 个月内长期使用高剂量苯二氮䓬类药物是显著的,并与死亡风险增加相关。考虑到 ICU 入院人数众多,预防苯二氮䓬类药物滥用可能会改善重症监护后的长期预后。